250 related articles for article (PubMed ID: 34009369)
21. National differences in cost analysis of Afirma Genomic sequencing classifier.
Ronen O; Oichman M
Clin Endocrinol (Oxf); 2021 Apr; 94(4):717-724. PubMed ID: 33349964
[TBL] [Abstract][Full Text] [Related]
22. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.
Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD
Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199
[No Abstract] [Full Text] [Related]
23. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.
Patel KN; Angell TE; Babiarz J; Barth NM; Blevins T; Duh QY; Ghossein RA; Harrell RM; Huang J; Kennedy GC; Kim SY; Kloos RT; LiVolsi VA; Randolph GW; Sadow PM; Shanik MH; Sosa JA; Traweek ST; Walsh PS; Whitney D; Yeh MW; Ladenson PW
JAMA Surg; 2018 Sep; 153(9):817-824. PubMed ID: 29799911
[TBL] [Abstract][Full Text] [Related]
24. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review.
Hier J; Avior G; Pusztaszeri M; Krasner JR; Alyouha N; Forest VI; Hier MP; Mlynarek A; Richardson K; Sadeghi N; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Apr; 50(1):29. PubMed ID: 33910629
[TBL] [Abstract][Full Text] [Related]
25. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
[TBL] [Abstract][Full Text] [Related]
26. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
[TBL] [Abstract][Full Text] [Related]
27. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
[TBL] [Abstract][Full Text] [Related]
28. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
[TBL] [Abstract][Full Text] [Related]
29. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy.
Bellevicine C; Migliatico I; Sgariglia R; Nacchio M; Vigliar E; Pisapia P; Iaccarino A; Bruzzese D; Fonderico F; Salvatore D; Biondi B; Masone S; Novizio V; Scavuzzo F; Serino D; De Palma M; Chiofalo MG; Botti G; Pezzullo L; Nuzzo V; Spiezia S; De Chiara G; Iorio S; Conzo G; Docimo G; Faggiano A; Bongiovanni M; Malapelle U; Colao A; Triassi M; Troncone G;
Cancer Cytopathol; 2020 Feb; 128(2):107-118. PubMed ID: 31821746
[TBL] [Abstract][Full Text] [Related]
31. Atypical de Quervain's thyroiditis diagnosed as atypia of undetermined significance by cytology and suspicious for cancer by Afirma Genomic Sequencing Classifier.
Yu R; Yang SE; Rao J
Diagn Cytopathol; 2021 Aug; 49(8):E312-E315. PubMed ID: 33656790
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of cytologically indeterminate thyroid nodules managed with Genomic Sequencing Classifier.
Ahmadi S; Kotwal A; Bikas A; Xiang P; Goldner W; Patel A; Hughes EG; Longstaff X; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2024 Feb; ():. PubMed ID: 38415829
[TBL] [Abstract][Full Text] [Related]
33. Preoperative molecular testing in thyroid nodules with Bethesda VI cytology: Clinical experience and review of the literature.
Labourier E; Fahey TJ
Diagn Cytopathol; 2021 Apr; 49(4):E175-E180. PubMed ID: 33052631
[TBL] [Abstract][Full Text] [Related]
34. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
Kloos RT; Reynolds JD; Walsh PS; Wilde JI; Tom EY; Pagan M; Barbacioru C; Chudova DI; Wong M; Friedman L; LiVolsi VA; Rosai J; Lanman RB; Kennedy GC
J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
[TBL] [Abstract][Full Text] [Related]
35. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules.
Eszlinger M; Krogdahl A; Münz S; Rehfeld C; Precht Jensen EM; Ferraz C; Bösenberg E; Drieschner N; Scholz M; Hegedüs L; Paschke R
Thyroid; 2014 Feb; 24(2):305-13. PubMed ID: 23837487
[TBL] [Abstract][Full Text] [Related]
36. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
Hang JF; Westra WH; Cooper DS; Ali SZ
Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601
[TBL] [Abstract][Full Text] [Related]
37. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
Zhu QL; Faquin WC; Samir AE
AJR Am J Roentgenol; 2015 Oct; 205(4):861-5. PubMed ID: 26397337
[TBL] [Abstract][Full Text] [Related]
38. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
39. Cytomorphological and molecular genetic findings in pediatric thyroid fine-needle aspiration.
Monaco SE; Pantanowitz L; Khalbuss WE; Benkovich VA; Ozolek J; Nikiforova MN; Simons JP; Nikiforov YE
Cancer Cytopathol; 2012 Oct; 120(5):342-50. PubMed ID: 22605559
[TBL] [Abstract][Full Text] [Related]
40. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
Parajuli S; Jug R; Ahmadi S; Jiang XS
Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
